Indaptus Therapeutics (INDP) reported Thursday new data from an ongoing phase 1 trial of Decoy20, which validated Decoy20's ability to modulate a patient's immune system in a "controlled and potentially meaningful way."
The biotechnology company said weekly treatment with Decoy20 led to broad immune cell trafficking that is a key pharmacodynamic marker, which is "critical for successful anti-tumor therapy," Indaptus Chief Scientific Officer Michael Newman said.
INDP shares were 3% lower in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.